Galectin Therapeutics (NASDAQ:GALT) Insider Khurram Jamil Sells 13,055 Shares

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 13,055 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $4.20, for a total value of $54,831.00. Following the completion of the transaction, the insider directly owned 46,945 shares of the company’s stock, valued at approximately $197,169. The trade was a 21.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Khurram Jamil also recently made the following trade(s):

• On Tuesday, January 6th, Khurram Jamil sold 21,446 shares of Galectin Therapeutics stock. The shares were sold at an average price of $3.65, for a total value of $78,277.90.
• On Monday, January 5th, Khurram Jamil sold 25,499 shares of Galectin Therapeutics stock. The shares were sold at an average price of $3.90, for a total value of $99,446.10.
• On Wednesday, December 17th, Khurram Jamil sold 19,442 shares of Galectin Therapeutics stock. The stock was sold at an average price of $7.04, for a total transaction of $136,871.68.
• On Thursday, November 13th, Khurram Jamil sold 121,117 shares of Galectin Therapeutics stock. The shares were sold at an average price of $5.47, for a total transaction of $662,509.99.

Galectin Therapeutics Trading Down 11.1%

Shares of NASDAQ:GALT traded down $0.43 during trading on Tuesday, reaching $3.45. The stock had a trading volume of 905,529 shares, compared to its average volume of 684,117. The firm’s 50-day simple moving average is $5.34 and its 200 day simple moving average is $4.39. Galectin Therapeutics Inc. has a one year low of $1.07 and a one year high of $7.13. The company has a market capitalization of $222.42 million, a P/E ratio of -5.85 and a beta of 1.03.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities research analysts forecast that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Galectin Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nuveen LLC acquired a new stake in Galectin Therapeutics during the 1st quarter worth about $34,000. Atwood & Palmer Inc. purchased a new position in shares of Galectin Therapeutics in the third quarter worth about $42,000. Archer Investment Corp purchased a new position in shares of Galectin Therapeutics in the third quarter worth about $47,000. Bank of America Corp DE boosted its position in Galectin Therapeutics by 101.4% in the fourth quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock valued at $49,000 after buying an additional 19,316 shares during the last quarter. Finally, Hudson Bay Capital Management LP acquired a new position in Galectin Therapeutics in the 3rd quarter worth approximately $63,000. Hedge funds and other institutional investors own 11.68% of the company’s stock.

More Galectin Therapeutics News

Here are the key news stories impacting Galectin Therapeutics this week:

• Negative Sentiment: CEO Joel Lewis sold multiple blocks of stock (Jan. 2, Jan. 5 and Jan. 6), totaling 83, (serial sales of 18,571; 27,731; 37,698 shares) at average prices around $4.20–$3.58, reducing his stake by ~4% overall — signaling significant insider liquidity. CEO Joel Lewis Form 4
• Negative Sentiment: CFO Jack W. Callicutt also executed staged sales (Jan. 2, Jan. 5 and Jan. 6), selling roughly 59, (13,914; 25,732; 20,354 shares) at avg. prices ~$4.20–$3.67, cutting his direct holdings by a large percentage — another material insider reduction. CFO Jack W. Callicutt Form 4
• Negative Sentiment: Director/insider Khurram Jamil sold multiple tranches (Jan. 2, Jan. 5 and Jan. 6) totaling ~60,000+ shares across those dates at avg. prices from $4.20 to $3.65, substantially reducing his position — further insider selling pressure. Khurram Jamil Form 4
• Negative Sentiment: Pomerantz LLP announced an investor investigation into Galectin on Jan. 6, which can increase legal risk and heighten short‑term selling pressure. Pomerantz Investor Alert

Analyst Ratings Changes

Several brokerages recently weighed in on GALT. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research note on Wednesday, October 8th. HC Wainwright raised their price target on Galectin Therapeutics from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $11.00.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.